Streptococcus pneumoniae capsular polysaccharide (serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) (PnPS)

Streptococcus pneumoniae capsular polysaccharides are the primary virulence factors of the pneumococcus bacterium, forming a protective outer layer that inhibits phagocytosis by host immune cells [4, 10]. These polysaccharides are chemically diverse, with over 100 distinct serotypes identified to date, each eliciting a specific immune response [4, 10]. In the GSK2830930A (also known as ASP3772) formulation, 24 specific capsular polysaccharides are included: serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F [1, 2]. Unlike traditional conjugate vaccines, GSK2830930A utilizes the Multiple Antigen Presenting System (MAPS) technology, which non-covalently links the polysaccharides to protein antigens to stimulate both humoral and cellular immunity [1, 3]. The target's role in disease involves facilitating bacterial colonization and invasion of the bloodstream or central nervous system, leading to conditions such as pneumonia, sepsis, and meningitis [3, 10]. By targeting these polysaccharides, the vaccine induces opsonophagocytic antibodies that facilitate the clearance of the bacteria by the host immune system [1, 3]. This broad-spectrum approach aims to provide protection against a significant majority of serotypes responsible for invasive pneumococcal disease globally [1, 2]. The inclusion of additional serotypes like 2, 9N, 17F, and 20 expands coverage beyond existing 20-valent vaccines [2, 6]. Clinical evaluation of these targets focuses on the induction of functional antibodies measured by opsonophagocytic activity assays [1, 3]. Overall, these polysaccharides represent critical targets for preventing the high morbidity and mortality associated with pneumococcal infections [3, 10].

Other names

Pneumococcal capsular polysaccharideCPSPnPSPneumococcal antigen

Induction of serotype-specific opsonophagocytic antibodies (IgG) and T-cell mediated immune responses through the Multiple Antigen Presenting System (MAPS) platform.